X

Drug Profile

MORF 088

Alternative Names: MORF-088

Latest Information Update: 22 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Morphic Therapeutic
Developer Eli Lilly and Company
Class Small molecules
Mechanism of Action Integrin alphavbeta8 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Myelofibrosis

Most Recent Events

16 Aug 2024 Morphic Therapeutic has been acquired and merged into Eli Lilly and Company
03 Aug 2023 Preclinical trials in Myelofibrosis in USA (PO)
03 Aug 2023 Morphic Therapeutic plans a clinical trial for Myelofibrosis in the first half of 2024 (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com